Lambrolizumab (MK-3475) Safe, Exhibits Early Evidence of Anti-Melanoma Activity

Share this article:

CHICAGO―Lambrolizumab is safe and exhibits anti-melanoma tumor activity, regardless of previous ipilimumab (IPI) treatment history, according to results of an ongoing phase 1b expansion study presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting and published online by the New England Journal of Medicine.

“Preliminary data suggest that lambrolizumab has significant antitumor activity and is well tolerated with manageable side effects in both IPI-naïve and IPI-pretreated melanoma patients,” reported Antoni Ribas, MD, PhD, of the University of California Los Angeles, and coauthors. The overall response rate across all doses and schedules, as confirmed by central review using RECIST 1.1 criteria, was 38%, the coauthors reported.

Programmed death (PD)-1 is an inhibitory T-cell co-receptor that might suppress antitumor immunity, the coauthors noted. Lambrolizumab is a humanized anti-PD-1 monoclonal IgG4 antibody.

The coauthors enrolled 135 patients diagnosed with advanced melanoma (87 IPI-naïve patients; 48 IPI-pretreated patients), administering lambrolizumab at 10 mg/kg intravenously every 2 weeks (n=57; 41 ipilimumab-naïve) or 3 weeks (n=56; 24 ipilimumab-naïve), or 2 mg/kg (n=22, all ipilimumab-naïve) every 3 weeks until disease progression or unacceptable toxicity, the coauthors reported.

“Responses were durable in the majority of patients” who experienced response, at a median follow-up of 11 months, the authors reported: 42 (81%) of patients with a response were continuing with treatment as of March 2013. 

The most common drug-related adverse events (AEs), as expected, were fatigue (30.4% all grades; 1.5% grade 3/4), rash (20.7%; 2.2% grade 3/4), and pruritus (20.7%; 0.7% grade 3/4), Dr. Ribas noted. A total of 107 (79%) patients experienced at least one drug-related AE, but most were manageable low-grade fevers and rashes, he said. Only 17 (12.6%) patients experienced a grade 3 or 4 drug-related AE (23% in the 10 mg/kg every 2 weeks group, 4% in the 10 mg/kg every 3 weeks group, and 9% in the 2 mg/kg group), he said.   Patients in the 10 mg/kg every 2 weeks group were on therapy for a median 40.1 weeks, compared to 20.6 weeks and 18.1 weeks among the 10 mg/kg every 3 weeks and the 2 mg/kg every 3 weeks groups, Dr. Ribas noted.

AEs of an inflammatory or immune nature included grade 1/2 pneumonitis in 4.4% of patients and hypothyroidism in 8.1% of patients. (One case of grade 3 hyperthyroidism was seen, and this patient also suffered grade 2 adrenal insufficiency, Dr. Ribas said.)

“Most treatment-related AEs were successfully managed with treatment discontinuation, supporting care and, occasionally, glucocorticoids,” Dr. Ribas said.

Confirmed objective responses were “rapid and durable” among patients who saw a benefit, Dr. Ribas said, adding that it is possible that longer follow-up will reveal objective responses or become partial or even complete responses.

“The longer we wait, it's possible we will see better responses,” he said.

“These data have led to an ongoing, international, randomized study of lambrolizumab versus chemotherapy in IPI-pretreated melanoma,” Dr. Ribas and his coauthors reported.

The study received support from Merck Sharp and Dohme.

Share this article:

Related Resources

You must be a registered member of Chemotherapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in ASCO 2013

Pazopanib Maintenance Therapy Delays Relapse in Advanced Ovarian Cancer

Maintenance therapy with pazopanib after successful initial chemotherapy for advanced ovarian cancer prolongs time to relapse and PFS compared to placebo, found research presented at ASCO 2013.

Adjuvant Bevacizumab Well-Tolerated in Patients with Melanoma at High Risk of Recurrence

In patients with melaoma at high risk of recurrence, adjuvant bevacizumab is well tolerated and improves the disease-free interval, found research presented at ASCO 2013.

No Increased Cardiac Toxicity with Dual HER2 Blockade Therapy for Breast Cancer

Combined anti-HER2 therapy, with or without chemotherapy, does not increase the risk for cardiac toxicities compared to anti-HER2 monotherapy, found research presented at ASCO 2013.